May 6 - 9, 2017
Westin Boston Waterfront
Abstract submission deadline: Thursday, March 9
Advance registration deadline: Thursday, March 30
May 6-9, 2017Westin Boston WaterfrontBoston, Massachusetts
Extended Abstract Submission and Award Application Deadline: Thursday, March 9, 2017Extended Advance Registration Deadline: Thursday, March 30, 2017
Conference Chair:Jonathan D. Licht, University of Florida Health Cancer Center, Gainesville, Florida
Conference Cochairs:Lucy A. Godley, University of Chicago, Chicago, IllinoisLouis M. Staudt, National Cancer Institute, Bethesda, MarylandCatherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
Scientific Program CommitteeJulian Adams, Infinity Pharmaceuticals, Inc., Boston, MassachusettsRajesh Chopra, The Institute Of Cancer Research, London, EnglandCarlo M. Croce, Ohio State University Comprehensive Cancer Center, Columbus, OhioRiccardo Dalla-Favera, Columbia University Institute for Cancer Genetics, New York, New YorkFaith E. Davies, University of Arkansas for Medical Sciences, Little Rock, ArkansasJohn E. Dick, University of Toronto, Toronto, Ontario, CanadaAdolfo Ferrando, Columbia University, New York, New YorkCatriona H. M. Jamieson, UCSD Moores Cancer Center, La Jolla, CaliforniaRicky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, AustraliaRoss L. Levine, Memorial Sloan Kettering Cancer Center, New York, New YorkMignon L. Loh, University of California, San Francisco, San Francisco, CaliforniaRavindra Majeti, Stanford University, Stanford, CaliforniaAri M. Melnick, Weill Cornell Medical College, New York, New YorkStanley R. Riddell, Fred Hutchinson Cancer Research Center, Seattle, WashingtonVeronika Sexl, VetmedUni, Institute of Pharmacology and Toxicology, Vienna, AustriaKimberly Stegmaier, Dana-Farber Cancer Institute, Boston, MassachusettsRodger E. Tiedemann, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Join us for the Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies! This conference will include presentations pertaining to leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms, spanning the spectrum of cancer science and medicine, from basic science discoveries to their translation in the clinic. Plenary sessions will be centered on scientific topics relevant to all blood cancers, such as genomics, epigenetics, cell death pathways, the tumor microenvironment, and chemical biology, as well as translational and clinical topics such as resistance and response to therapy, immunotherapy, and more.
This conference offers a unique opportunity for a lively discussion, in a small setting, of the challenges in the field among basic, translational, and clinical researchers, and for potential collaborations between national and international investigators.
There will be ample opportunities for networking, both with colleagues over scientific topics and with the stellar roster of invited speakers. Additionally, short talks from submitted abstracts will be selected for inclusion in the plenary sessions.
Make plans to join us this May in Boston for a program that will be appealing and of collaborative and educational benefit for scientists and clinicians studying any of the hematologic malignancies!Continuing Medical Education Activity AMA PRA Category 1 CreditsTM available